Skip to main content
Fig. 1 | Acta Neuropathologica Communications

Fig. 1

From: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

Fig. 1

PBT434 enhances the release of iron and prevents the generation of hydrogen peroxide. Cultured M17 neuroblastoma cells were loaded with the iron isotope 59Fe. The cells were washed and then exposed to a chelator to assess if iron could be removed from the cell. Cells loaded with the iron isotope 59Fe were exposed to a PBT434 and the amount of radioactive 59Fe released into the media was measured (CPM = counts per minute) or b deferiprone at 0, 1, 10 or 20 μM for 3 h. Deferiprone showed a dose related increase in the levels of 59Fe secreted into growth medium. With PBT434 the effect was observed only at the highest dose of 20 μM (*P < 0.05, ** P < 0.01, *** P < 0.0001, One-way ANOVA, Tukey Post Hoc). At the highest concentration, the effect of deferiprone was 5-fold greater than for PBT434. The dashed line represents equivalent values on the two graphs. c PBT434 causes an inhibition of metal mediated redox activity. Fe-citrate (0.4 μM) in the presence of dopamine (DA, 50 mM) generate hydrogen peroxide (H2O2) assessed using a cell-free fluorescence-based assay. PBT434 at 10 μM but not PBT434-met significantly reduced H2O2 generated by Fe/DA (PBT434-met = analog of PBT434 in which the metal binding site is blocked; One-way ANOVA, Tukey Post Hoc). Dopamine without Fe-Citrate did not produce H2O2

Back to article page